Clinical Study

Ucci-Hn-17-02 An Open-Label, Phase II Study Of Durvalumab (Medi4736) In Combination With Cetuximab In Previously Treated Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (Hnscc)

Posted Date: May 20, 2019

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to determine the objective response rate of the combination of Durvalumab and Cetuximab using RECIST 1.1 in subjects with recurrent and/or metastatic HNSCC who have progressed following platinum therapy.


To Be Eligible: Age 18 Or Older, Bodyweight >30Kg, Must Have Recurrent Or Metastatic Hnscc, No Other Malignancy Within 5 Years


Head And Neck Cancer, Recurrent, Metastatic

For More Information:

Uccc Clinical Trials Office

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.